Pear Therapeutics launches Somryst for chronic insomnia
Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
10 promising digital therapeutics
Today, we are witnessing an upsurge in health concerns. More than half of the population has diabetes, fluctuating blood pressure, and mental health issues....
Orexo launches digital therapeutics using Accenture’s INTIENT platform
The solution, called vorvida, is launching for patients in the United States dealing with problematic alcohol use.
Pear Therapeutics publishes real-world utilization data for reSET-O
Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
Juniper: There will be 1.4B digital therapeutics and wellness app users by 2025
The growth comes after regulators responded to COVID-19 by loosening rules that had previously hindered the work of digital therapeutics developers.
PreferredOne taps Pear to become the first health plan to cover digital therapeutics
PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.
Digital Therapeutics Alliance establishes foundational definition, industry core principles
Digital therapeutics is a new category of medical interventions that combine patient-centric technologies with evidence-based medicine to deliver personalized care.
Magellan Health to pilot PEAR Therapeutics’ digital therapeutic reSET
The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
Digital therapeutics organizations band together to promote their industry
Personal Connected Health Alliance and Digital Therapeutics Alliance have formed a strategic partnership to advance the field of digital therapeutics.